BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Other names | Brilife |
Routes of administration | Intramuscular |
ATC code |
|